Comparative Pharmacology
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus PROCHLORPERAZINE MALEATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLUPHENAZINE DECANOATE versus PROCHLORPERAZINE MALEATE.
FLUPHENAZINE DECANOATE vs PROCHLORPERAZINE MALEATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluphenazine decanoate is a long-acting phenothiazine antipsychotic. It exerts its effects by blocking postsynaptic dopamine D2 receptors in the mesolimbic pathway, and also has antagonistic activity at alpha-1 adrenergic, muscarinic, and histamine H1 receptors, contributing to its side effect profile.
Prochlorperazine is a phenothiazine antipsychotic that primarily antagonizes dopamine D2 receptors in the chemoreceptor trigger zone (CTZ) and central nervous system. It also has anticholinergic and antiemetic effects through blockade of histamine H1 and muscarinic M1 receptors.
12.5-25 mg deep IM injection every 2-4 weeks, not exceeding 100 mg per dose.
5-10 mg orally 3-4 times daily; or 25 mg rectally twice daily; or 5-10 mg intramuscularly every 3-4 hours up to 40 mg/day; or 2.5-10 mg intravenously slowly at 2.5 mg/min, maximum 20 mg/day.
None Documented
None Documented
Terminal elimination half-life is approximately 14 days (range 7-21 days) following IM injection, reflecting slow release from depot and prolonged redistribution.
Terminal elimination half-life is approximately 6-8 hours in adults, but may extend up to 12-15 hours after chronic dosing or in hepatic impairment.
Primarily renal (metabolites) and fecal (biliary). Estimated 50% renal, 50% fecal as metabolites.
Primarily renal (70-80% as metabolites, <1% unchanged); fecal/biliary excretion accounts for 20-30% via enterohepatic circulation.
Category A/B
Category A/B
Typical Antipsychotic
Typical Antipsychotic / Antiemetic